Furthermore, these results may suggest the possibility of treating KMT2A-rearranged MECs using azacytidine and venetoclax, as these treatments have shown promising outcomes in the treatment of KMT2A-rearranged leukemias [21]. Here, KMT2A is linked to leukemia.